首页|基于FAERS数据库对舒尼替尼不良事件信号挖掘和用药风险分析

基于FAERS数据库对舒尼替尼不良事件信号挖掘和用药风险分析

扫码查看
目的 基于美国食品药品管理局不良事件报告系统(FAERS)数据库挖掘舒尼替尼不良事件(AE)信号,为合理用药提供参考。方法 应用报告比值法(ROR)、比例报告比值比法(PRR)、多项式伽马泊松分布缩减法(MGPS)和贝叶斯可信区间递进神经网络法(BCPNN)分析FAERS数据库2006年第一季度至2023年第三季度舒尼替尼的数据风险信号强度。结果 检索到舒尼替尼AE报告35 720份,阳性信号310个;大多数AE发生在用药后30 d(39。71%);严重AE占76。37%;阳性信号共涉及27个系统器官分类(SOC),前3位为全身性疾病及给药部位各种反应、胃肠系统疾病和各类检查;死亡、腹泻、疾病进展和疲劳等发生频次较高;发生强度前20位AE中,新的不良反应占65%,如肿瘤破裂和葡萄膜黑色素细胞弥漫性增殖等。结论 应完善舒尼替尼用药评估,加强用药监护,保证患者安全用药。
Adverse Event Signal Mining and Drug Risk Analysis of Sunitinib Based on FAERS Database
Objective To explore adverse event(AE)signals of sunitinib and to provide a reference for rational drug monitoring based on the Food and Drug Administration Adverse Event Reporting System(FAERS)database.Methods Report odds ratio method(ROR),proportional report ratio method(PRR),polynomial gamma Poisson distribution reduction method(MGPS),and Bayesian confidence interval progressive neural network method(BCPNN)were used to detect the data risk signal strength of sunitinib from the first quarter of 2006 to the third quarter of 2023.Results A total of 35 720 AE reports of sunitinib were retrieved,with 310 positive signals.Most AEs occurred in the first 30 days after treatment(39.71%).Serious AE accounted for 76.37%;27 system organ classifications(SOCs)were involved in positive signals,and the top three were systemic diseases,various reactions at the administration site,gastrointestinal system diseases,and various examinations.High frequency of death,diarrhea,disease progression,and fatigue;65%of the top 20 AEs were new adverse reactions,such as tumor rupture and diffuse proliferation of uveal melanocytes.Conclusion The evaluation of sunitinib should be improved,and medication monitoring should be strengthened to ensure the safety of patients.

SunitinibAdverse eventsFood and Drug Administration Adverse Event Reporting System(FAERS)databaseSignal mining

李素素、马曾庆、吴连平、赵欣

展开 >

江苏大学附属高淳医院药学部,南京 211300

舒尼替尼 不良事件 美国食品药品管理局不良事件报告系统 信号挖掘

2025

医药导报
中国药理学会 华中科技大学同济医学院附属同济医院 中国医药商业协会

医药导报

北大核心
影响因子:1.042
ISSN:1004-0781
年,卷(期):2025.44(1)